23 May 2013
Keywords: repligen, drug, autism, misses, mark, experimental, treatment
Article | 05 April 2001
Repligen's experimental treatment for autism, human synthetic secretin,has failed to achieve its primary endpoint in a Phase II trial ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 June 2001
© 2013 thepharmaletter.com